



DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

September 3, 2024

Matthew D'Onofrio
Chief Executive Officer
Evoke Pharma, Inc.
420 Stevens Avenue, Suite 230
Solana Beach, CA 92075

Re: Evoke Pharma, Inc.
Registration Statement on Form S-3
Filed August 29, 2024
File No. 333-281840

Dear Matthew D'Onofrio:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Alan Campbell at 202-551-4224 with any questions.

Sincerely,

Division of Corporation Finance
Office of Life Sciences

cc: Anthony A. Gostanian, Esq.